66
Participants
Start Date
February 28, 2009
Primary Completion Date
July 31, 2012
Study Completion Date
July 31, 2012
PCI-32765
"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
New York Prebyterian Hospital Cornell Medical Center, New York
University of Chicago, Chicago
University of Texas, MD Anderson, Houston
Stanford University School of Medicine, Palo Alto
Willamette Valley Cancer Institute/Research Ctr, Eugene
Northwest Cancer Specialists, Vancouver Cancer Center, Vancouver
Yakima Valley Memorial Hospital/North Star Lodge Cancer Ctr, Yakima
National Cancer Institute, Bethesda
University of Vermont College of Medicine, Burlington
Lead Sponsor
Pharmacyclics LLC.
INDUSTRY